(19)
(11) EP 4 771 043 A1

(12)

(43) Date of publication:
08.07.2026 Bulletin 2026/28

(21) Application number: 24858887.3

(22) Date of filing: 28.08.2024
(51) International Patent Classification (IPC): 
C07K 14/705(2006.01)
C12N 5/0784(2010.01)
A61P 35/00(2006.01)
A61K 38/00(2006.01)
(52) Cooperative Patent Classification (CPC):
A61K 38/00; A61P 35/00; C07K 14/70596; C07K 2319/00
(86) International application number:
PCT/IB2024/058377
(87) International publication number:
WO 2025/046493 (06.03.2025 Gazette 2025/10)
(84) Designated Contracting States:
AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC ME MK MT NL NO PL PT RO RS SE SI SK SM TR
Designated Extension States:
BA
Designated Validation States:
GE KH MA MD TN

(30) Priority: 30.08.2023 US 202363579643 P

(71) Applicant: Janssen Biotech, Inc.
Horsham, PA 19044 (US)

(72) Inventors:
  • TAMOT, Ninkka
    Spring House, Pennsylvania 19477 (US)
  • HARVILLA, Paul Byron
    Raritan, New Jersey 08869 (US)

(74) Representative: Carpmaels & Ransford LLP 
One Southampton Row
London WC1B 5HA
London WC1B 5HA (GB)

   


(54) BIOENGINEERED IMMUNOMODULATORY FUSION PROTEIN COMPOSITIONS